This is a randomized, double-blind, placebo-controlled, parallel-group, multi-national study REGN727 (SAR236553) in patients with Heterozygous Familial Hypercholesterolemia (heFH) who are not adequately controlled with their Lipid-Modifying Therapy (LMT).